196 results on '"Feng, Joy"'
Search Results
2. Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro
3. Structural basis for substrate selection by the SARS-CoV-2 replicase
4. The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses
5. Mechanism and spectrum of inhibition of a 4′-cyano modified nucleotide analog against diverse RNA polymerases of prototypic respiratory RNA viruses
6. Discovery of GS-7682, a Novel 4′-Cyano-Modified C-Nucleoside Prodrug with Broad Activity against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green Monkeys
7. Efforts and Concerns for Indigenous Language Education in Taiwan
8. 539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for Obeldesivir
9. HCV RdRp, sofosbuvir and beyond
10. Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys
11. Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement
12. Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential
13. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
14. Interfering with nucleotide excision by the coronavirus 3′-to-5′ exoribonuclease
15. Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus
16. Structural basis for RNA replication by the hepatitis C virus polymerase
17. Efforts and Concerns for Indigenous Language Education in Taiwan
18. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
19. The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2
20. Structural basis for substrate selection by the SARS-CoV-2 replicase
21. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
22. Efficient Incorporation and Template‐Dependent Polymerase Inhibition are Major Determinants for the Broad‐Spectrum Antiviral Activity of Remdesivir
23. Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity
24. Interfering with nucleotide excision by the coronavirus 3′-to-5′ exoribonuclease
25. Correction: Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action
26. Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA
27. Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir
28. An atomistic model of the coronavirus replication-transcription complex as a hexamer assembled around nsp15
29. Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice
30. Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells
31. Response to Yan and Muller “Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver”
32. VIRAL REPLICATION: Structural basis for RNA replication by the hepatitis C virus polymerase
33. Structural and kinetic insights into binding and incorporation of L-nucleotide analogs by a Y-family DNA polymerase
34. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
35. Species-Specific Urothelial Toxicity With an Anti-HIV Noncatalytic Site Integrase Inhibitor (NCINI) Is Related to Unusual pH-Dependent Physicochemical Changes
36. Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
37. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
38. Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent
39. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action
40. Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.
41. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
42. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
43. Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice
44. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition
45. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
46. Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation
47. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
48. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
49. The KN-93 Molecule Inhibits Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII) Activity by Binding to Ca2+/CaM
50. Discovery of a 2′-fluoro-2′-C-methyl C-nucleotide HCV polymerase inhibitor and a phosphoramidate prodrug with favorable properties
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.